Aurora B kinase and malignant mesothelioma.

Betta, Pier Giorgio; Bensi, T.; Trincheri, Nicol F.; Arnolfo, E.; Libener, Roberta; Botta, Mario; Piccolini, E.; Bottero, G; Grosso, Fabio; Orecchia, Sara

doi:10.1200/jco.2010.28.15_suppl.e21021

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sak and colleagues [ 58 ] showed that inhibition of AURKB with low AZD1152-hydroxyquinazoline pyrazol anilide (AZD 1152-HQPA) concentrations concomitant to radiotherapy negatively affects repopulation of NSCLC cell lines, indicating the combined efficacy of AURKB inhibition and irradiation in regrowth of lung cancer cells. In another study, varying concentrations of AZD 1152-HQPA conferred a reduction in cell viability and ensued apoptotic cell death in four malignant mesothelioma cell lines, but without considerable effect on the level of AURKB expression at the translational level [ 59 ].…”

Section: Pre-clinical Studies On Aurora Kinasesmentioning

confidence: 99%

Promising Therapy in Lung Cancer: Spotlight on Aurora Kinases

Galetta

Cortes-Dericks

2020

Cancers

View full text Add to dashboard Cite

Despite tremendous efforts to improve the treatment of lung cancer, prognosis still remains poor; hence, the search for efficacious therapeutic option remains a prime concern in lung cancer research. Cell cycle regulation including mitosis has emerged as an important target for cancer management. Novel pharmacological agents blocking the activities of regulatory molecules that control the functional aspects of mitosis such as Aurora kinases are now being investigated. The Aurora kinases, Aurora-A (AURKA), and Aurora B (AURKB) are overexpressed in many tumor entities such as lung cancer that correlate with poor survival, whereby their inhibition, in most cases, enhances the efficacy of chemo-and radiotherapies, indicating their implication in cancer therapy. The current knowledge on Aurora kinase inhibitors has increasingly shown high potential in ensuing targeted therapies in lung malignancies. In this review, we will briefly describe the biology of Aurora kinases, highlight their oncogenic roles in the pre-clinical and clinical studies in lung cancer and, finally, address the challenges and potentials of Aurora kinases to improve the therapy of this malignancy.

show abstract

Section: Pre-clinical Studies On Aurora Kinasesmentioning

confidence: 99%

Promising Therapy in Lung Cancer: Spotlight on Aurora Kinases

Galetta

Cortes-Dericks

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Pre-clinical studies of human tumor cultures and murine xenograft models using single-agent AZD1152 have been conducted in numerous tumor types, including breast61,62, pancreas62, colorectal62,63,64,65,66, non-small cell lung63,64, small cell lung67, hepatocellular carcinoma68, malignant mesothelioma69, AML62,70,71,72, and multiple myeloma (MM)73. AZD1152 is also a potent FLT3 inhibitor, potentially adding a dual mechanism to the antitumor effects in AML 74.…”

Section: 0 Aurora B Kinase-specific Inhibitorsmentioning

confidence: 99%

Update on Aurora Kinase Inhibitors in Gynecologic Malignancies

Tao

Chon

et al. 2008

PRA

View full text Add to dashboard Cite

Introduction Mammalian cells contain three distinct serine/threonine protein kinases with highly conserved catalytic domains, including aurora A and B kinases that are essential regulators of mitotic entry and progression. Overexpression of aurora A and/or B kinase is associated with high proliferation rates and poor prognosis, making them ideal targets for anti-cancer therapy. Disruption of mitotic machinery is a proven anti-cancer strategy employed by multiple chemotherapeutic agents. Numerous small molecule inhibitors of the aurora kinases have been discovered and tested in vivo and in vitro, with a few currently in phase II testing. Areas covered This review provides the reader with updated results from both preclinical and human studies for each of the aurora kinase inhibitors (AKI) that are currently being investigated. The paper also covers in detail the late breaking and phase I data presented for AKIs thereby allowing the reader to compare and contrast individual and class-related effects of AKIs. Expert opinion While the successful development and approval of an AKI for anti-cancer therapy remains unresolved, pre-clinical identification of resistant mechanisms would help design better early phase clinical trials where relevant combinations may be evaluated prior to phase II testing. The authors believe that aurora kinases are important anti-cancer targets that operate in collaboration with other oncogenes intimately involved in uncontrolled tumor proliferation and by providing a unique, targeted and complimentary anti-cancer mechanism, expand the available armamentarium against cancer.

show abstract

Aurora B kinase and malignant mesothelioma.

Cited by 2 publications

References 0 publications

Promising Therapy in Lung Cancer: Spotlight on Aurora Kinases

Promising Therapy in Lung Cancer: Spotlight on Aurora Kinases

Update on Aurora Kinase Inhibitors in Gynecologic Malignancies

Contact Info

Product

Resources

About